Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, accounting for approximately 3%-5% of all melanoma cases. When it progresses to metastatic uveal melanoma (MUM), treatment becomes more complex and challenging. According to the metastatic uveal melanoma pipeline analysis by Expert Market Research, the drug development pipeline is gaining momentum, driven by a growing focus on targeted immunotherapies and precision medicine. There are various metastatic uveal melanoma therapies in the pipeline which has shown improved survival rates. The market is expected to witness steady growth in the coming years due to increased R&D investments and clinical advancements.
Major companies involved in the metastatic uveal melanoma pipeline analysis include IDEAYA Biosciences, Novartis Pharmaceuticals, and others.
Leading drugs currently in the pipeline include IDE196 + Crizotinib, BVD-523, DYP688, and others.
Rising clinical trials, increased FDA designations, and advancements in immunotherapies and targeted therapies are expected to significantly drive the growth of the metastatic uveal melanoma drug pipeline in the coming years.
The Metastatic Uveal Melanoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into metastatic uveal melanoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for metastatic uveal melanoma. The metastatic uveal melanoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The metastatic uveal melanoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with metastatic uveal melanoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to metastatic uveal melanoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Metastatic uveal melanoma is a rare and aggressive cancer that originates in the eye’s uveal tract and spreads to distant organs, most commonly the liver. It occurs when malignant cells from the primary uveal melanoma travel through the bloodstream or lymphatic system to form secondary tumors in other parts of the body.
Metastatic uveal melanoma treatment includes immunotherapy, targeted therapy, and chemotherapy. Options may vary based on genetic profile and disease progression. Tebentafusp-tebn is the first FDA-approved therapy for specific patients. In January 2022, the U.S. Food and Drug Administration approved tebentafusp-tebn (Kimmtrak) for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, following strong overall survival benefits shown in the IMCgp100-202 clinical trial.
According to Serena Salzano et al., 2025, uveal melanoma accounts for 3–5% of all melanoma cases, with an incidence of about 5 per million annually. Despite effective local control, up to 50% of patients develop metastatic disease, primarily in the liver. Median survival post-metastasis is 6-12 months, with a 1-year survival rate of 15%. Current drug pipeline efforts aim to improve survival and treatment efficacy.
This section of the report covers the analysis of metastatic uveal melanoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The metastatic uveal melanoma pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I (at 45%) covers a major share of the total metastatic uveal melanoma clinical trials. It is followed closely by phase II at 44%. Phase III accounts for 10%. The strong presence in phases I and II reflects a robust development pipeline, indicating significant potential for therapeutic advancements for metastatic uveal melanoma.
The drug molecule categories covered under the metastatic uveal melanoma pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules, and gene therapies. The metastatic uveal melanoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for metastatic uveal melanoma. Small molecule inhibitors are also emerging to provide effective treatment options for patients with metastatic uveal melanoma. For instance, roginolisib, an oral allosteric modulator of phosphoinositide-3-kinase delta (PI3Kδ), is under evaluation in a Phase II clinical trial. It works by selectively targeting PI3Kδ, thereby, potentially improving overall survival outcomes in patients who have progressed after prior therapies.
The EMR report for the metastatic uveal melanoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed metastatic uveal melanoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in metastatic uveal melanoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for metastatic uveal melanoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of metastatic uveal melanoma drug candidates.
IDE196, sponsored by IDEAYA Biosciences, is currently undergoing a Phase 2/3 trial as a first-line therapy for metastatic uveal melanoma in HLA-A2-negative patients. This study is evaluating the safety, tolerability, and anti-tumor activity of IDE196, a PKC inhibitor, in combination with crizotinib, a MET inhibitor. The trial is determining the optimal oral dosage to compare against standard immunotherapy options.
BVD-523 (Ulixertinib) is currently undergoing a Phase II clinical trial sponsored by Dana-Farber Cancer Institute. This study is evaluating BVD-523 as a potential treatment for metastatic uveal melanoma. The objective is to examine its safety and effectiveness in targeting ERK1/2 kinases, key drivers in the MAPK pathway. BVD-523 is an orally active, selective ERK1/2 inhibitor designed to suppress tumor growth by blocking abnormal protein signaling.
DYP688, sponsored by Novartis Pharmaceuticals, is currently undergoing a Phase I/II open-label, multi-center study targeting metastatic uveal melanoma and other melanomas with GNAQ/11 mutations. This first-in-human study is assessing the safety, tolerability, and anti-tumor activity of DYP688, a selective inhibitor designed to disrupt signaling pathways activated by GNAQ/11 mutations. The study is enrolling patients to evaluate dose escalation and therapeutic response in both tebentafusp-naïve and pre-treated groups.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Metastatic Uveal Melanoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for metastatic uveal melanoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into metastatic uveal melanoma collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share